at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on September 13, 2024, based on a complaint, as supplemented, filed by HydraFacial LLC f/k/a Edge Systems LLC of Long Beach, California (''HydraFacial''). 89 FR 74995–96 (September 13, 2024). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (''section 337''), based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain hydrodermabrasion systems and components thereof by reason of the infringement of certain claims of U.S. Patent No. 11,446,477 (''the '477 patent''). *Id.* The complaint also asserts that a domestic industry exists.

The Commission's notice of investigation names as respondents: Luvo Medical Technologies Inc. of Ontario, Canada; Clarion Medical Technologies, Inc. of Ontario, Canada; Healthcare Markets, Inc. d/b/a Powered by MRP of Park City, Utah; Medical Purchasing Resource, LLC of Little Elm, Texas; Bio-Infusions USA Inc. of Seminole, Florida; MIRAmedtech UG of Neulingen, Germany; eMIRAmed USA, LLC of Irvine, California; and MIRAmedtech SP. Z.O.O. of Warsaw, Poland. *Id.* The Office of Unfair Import Investigations is not participating in this investigation. *Id.*

On January 2, 2025, the Commission found respondent Medical Purchasing Resource, LLC in default. Order No. 7 (Dec. 9, 2024), *unreviewed by* Comm'n Notice (Jan. 2, 2025).

On February 6, 2025, the Commission found respondents Bio-Infusions USA Inc., MIRAmedtech UG, eMIRAmed USA, LLC, and MIRAmedtech SP. Z.O.O. in default. Order No. 13 (Jan. 17, 2025), *unreviewed by* Comm'n Notice (Feb. 6, 2025).

On April 10, 2025, HydraFacial filed a declaration under Commission Rule 210.16(c)(1) (19 CFR 210.16(c)(1)) (''Declaration'') requesting immediate entry of an LEO and CDOs against the Defaulting Respondents. HydraFacial also requested a bond in the amount of 100 percent of the entered value of the infringing articles imported during the period of Presidential review.

On April 24, 2025, the Commission issued a notice terminating the investigation as to the remaining active respondents, Clarion Medical Technologies, Inc., Luvo Medical Technologies, Inc., and Healthcare Markets, Inc. d/b/a Powered by MRP based on settlement agreements. Order No. 16 (April 4, 2025), *unreviewed by* Comm'n Notice, 90 FR 17259–61 (April 24, 2025) (''the Remedy Notice''). In the same notice, the Commission asked parties to the investigation, interested government agencies, and any other interested parties to file written submissions on the issues of remedy, the public interest, and bonding. *Id.*

On May 6, 2025, HydraFacial filed a written submission requesting the Commission to issue an LEO and CDOs against the Defaulting Respondents, and providing information requested by the Remedy Notice. The Commission received no other written submissions in response to the Remedy Notice.

When the conditions in section 337(g)(1)(A)–(E) (19 U.S.C. 1337(g)(1)(A)–(E)) have been satisfied, section 337(g)(1) and Commission Rule 210.16(c) (19 CFR 210.16(c)) direct the Commission, upon request, to issue a limited exclusion order or a cease and desist order or both against a respondent found in default, based on the allegations regarding a violation of section 337 in the complaint, which are presumed to be true, unless after consideration of the public interest factors in section 337(g)(1), it finds that such relief should not issue.

Having examined the record of this investigation, including HydraFacial's Declaration and its submission in response to the Remedy Notice, the Commission has determined, pursuant to section 337(g)(1) (19 U.S.C. 1337(g)(1)), that the appropriate remedy in this investigation is: (1) an LEO prohibiting the unlicensed entry of certain hydrodermabrasion systems and components thereof by reason of infringement of certain claims of the '477 patent by the Defaulting Respondents and (2) CDOs directed to the Defaulting Respondents. The Commission has determined that the public interest factors enumerated in subsection 337(g)(1) do not preclude the issuance of the LEO and CDOs. The Commission has further determined that the bond during the period of Presidential review pursuant to section 337(j) (19 U.S.C. 1337(j)) shall be in the amount of one hundred percent (100%) of the entered value of the imported articles that are subject to the LEO.

The investigation is terminated.

The Commission vote for this determination took place on May 27, 2025.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: May 27, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–09860 Filed 5–30–25; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1387]

Certain Electronic Computing Devices, and Components and Modules Thereof Notice of a Commission Determination Not To Review an Initial Determination Granting a Joint Motion To Terminate the Investigation in Its Entirety Based Upon Settlement

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (''Commission'') has determined not to review an initial determination (''ID'') (Order No. 39) of the presiding administrative law judge (''ALJ''), granting a joint motion to terminate the investigation in its entirety based upon settlement.

FOR FURTHER INFORMATION CONTACT: Panyin A. Hughes, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–3042. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205–1810.

SUPPLEMENTARY INFORMATION: On January 18, 2024, the Commission instituted this investigation based on a complaint filed by Telefonaktiebolaget LM Ericsson of Stockholm, Sweden

(''Ericsson''). 89 FR 3427–28 (Jan. 18, 2024). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain electronic computing devices, and components and modules thereof by reason of infringement of claims 1–3, 5–7, 9–11, 14, 15, and 16 of U.S. Patent No. 9,641,841 (''the '841 patent''); claims 1–7 and 10–16 of U.S. Patent No. 10,142,659 (''the '659 patent''); claims 1–19 of U.S. Patent No. 10,708,618 (''the '618 patent''); and claims 1–9 of U.S. Patent No. 10,708,613 (''the '613 patent''). *Id.* The Commission's notice of investigation named the following respondents: Lenovo (United States) Inc. of Morrisville, North Carolina; Lenovo (Shanghai) Electronics Technology Co., Ltd. of Shanghai, China; Lenovo Beijing Co., Limited of Beijing, China; Lenovo PC HK Limited of Hong Kong; Lenovo Information Products (Shenzhen) Co. Ltd. of Shenzhen, China (collectively, ''Lenovo''); and Lenovo Group Limited of Beijing, China (''LGL''). The Office of Unfair Import Investigations (''OUII'') was also named as a party in this investigation. *Id.*

The Commission terminated the investigation as to LGL because LGL does not import into the United States, sell for importation, or sell within the United States the accused products. Order No. 16 (Aug. 20, 2024), *unreviewed by* Comm'n Notice (Sept. 16, 2024).

The Commission terminated the investigation as to all asserted claims of the '613 patent, claims 1–8 and 10–19 of the '618 patent, claims 1–3, 5–7, 9, and 14–16 of the '841 patent, and claims 1–3, 5, 6, and 13–16 of the '659 patent. Order No. 17 (Sept. 9, 2024), *unreviewed by* Comm'n Notice (Oct. 8, 2024); Order No. 33 (Oct. 17, 2024), *unreviewed by* Comm'n Notice (Nov. 5, 2025).

On April 17, 2025, Ericsson and Lenovo filed a joint motion to terminate the investigation in its entirety based upon settlement. On April 28, 2025, OUII filed a response in support of the motion.

On May 8, 2025, the ALJ issued the subject ID (Order No. 39) granting the motion. The ID noted that Commission Rule 210.21(a)(2) provides that ''[a]ny party may move at any time to terminate an investigation in whole or in part as to any or all respondents on the basis of a settlement, a licensing or other agreement . . . .'' ID at 2. The ID found that the motion complies with Commission Rule 210.21(b). *Id.* at 2. The ID further found that in accordance with Commission Rule 210.21(b)(1), the motion states that apart from the Confidential Patent License Agreement and Confidential Arbitration Agreement ''there are no other agreements, written or oral, express or implied between the private parties concerning the subject matter of this Investigation.'' *Id.* at 3. The ID also found that terminating the investigation will not adversely impact the public interest. *Id.* No one petitioned for review of the ID.

The Commission has determined not to review the subject ID. The investigation is hereby terminated in its entirety.

The Commission vote for this determination took place on May 27, 2025. The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: May 28, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–09898 Filed 5–30–25; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1551]

Bulk Manufacturer of Controlled Substances Application: Veranova, L.P.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Veranova, L.P. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 1, 2025. Such persons may also file a written request for a hearing on the application on or before August 1, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 17, 2025, Veranova, L.P., 25 Patton Road, Pharmaceutical Service, Devens, Massachusetts 01434–3803, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic Acid Diethylamide	7315	I
3,4-Methylenedioxymethamphetamine	7405	I
Dimethyltryptamine	7435	I
Amphetamine	1100	II
Methylphenidate	1724	II
Nabilone	7379	II
Hydrocodone	9193	II
Levorphanol	9220	II
Thebaine	9333	II
Alfentanil	9737	II